Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Agenovir: Using Gene Editing To Kill Viral DNA

Executive Summary

Emerging Company Profile: Agenovir has a unique gene-editing niche – using CRISPR/Cas9 to destroy DNA in latent viral reservoirs as opposed to other companies that snip and repair errors in the genome.

Advertisement

Related Content

CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?
VC Roundup: Three New Funds Close As Small, Early Financings Bounce Back
BioNotebook: Spring heats up the IPO market
Cidara CEO Stein brings Trius gang, biotech vets together
AstraZeneca acquires rights to anti-infective from Forest

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099321

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel